11:01 AM EDT, 03/16/2026 (MT Newswires) -- Guardant Health ( GH ) plans to launch its Shield multicancer detection test in parts of Asia through a partnership with Manulife Financial ( MFC ) .

Eligible Manulife customers in Hong Kong, Singapore and the Philippines will gain access to the test starting in April, Guardant said Monday in a statement.

Shield is a methylation-based blood test designed to detect multiple cancers, including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and pancreatic, in individuals 45 or older who are at average risk, Guardant said.

The test has received breakthrough device designation from the US Food and Drug Administration based on its performance in a National Cancer Institute study, the company said.

Guardant shares rose 2% in Monday trading, and Manulife gained 1.8%.

Price: 87.19, Change: +1.70, Percent Change: +1.98